Multiple Myeloma (MM) is a hematologic malignancy involving clonal plasma cell proliferation. Unfortunately, MM remains an incurable disease. Over the past five years, the incorporation of novel monoclonal antibodies has synergized with standard of care to improve patient outcomes in both newly diagnosed MM as well as relapsed and refractory MM. This manuscript reviews current and prospective antibody-based treatments including naked monoclonal antibodies, immunoconjugates, and Bi-specific T-cell engagers (BiTE).
Keywords: Belantamab; BiTE; Daratumumab; Elotuzumab; Immunoconjugates; Isatuximab; Monoclonal antibody; Multiple myeloma.
Copyright © 2021. Published by Elsevier Inc.